Therapeutic standards in Alzheimer disease

Alzheimer Disease and Associated Disorders

Volumn 13, Issue SUPPL. 2, 1999, Pages

  Doody, Rachelle S ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Alzheimer disease; Clinical; Donepezil; Therapy; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; CHOLINESTERASE INHIBITOR; DONEPEZIL; INDAN DERIVATIVE; PIPERIDINE DERIVATIVE;

ALZHEIMER DISEASE; COGNITION; DAILY LIFE ACTIVITY; DRUG EFFECT; HEALTH CARE QUALITY; HUMAN; QUALITY OF LIFE; REVIEW; TREATMENT OUTCOME;

ACTIVITIES OF DAILY LIVING; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COGNITION; HUMANS; INDANS; PIPERIDINES; QUALITY OF HEALTH CARE; QUALITY OF LIFE; TREATMENT OUTCOME; VITAMIN E;

EID: 0033217323     PISSN: 08930341     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002093-199911002-00004     Document Type: Review

References (32)

1. Aisen PS, Pasinetti GM. Glucocorticoids in Alzheimer's disease. The story so far. Drugs Aging 1998;12:1-6.
2. Bartus RT, Dean RL, Beer B, Lippa AS. The cholinergic hypo-thesis of geriatric memory dysfunction. Science 1982;217:408-17.
3. Burns A, Rossor M, Hecker J, et al. The effects of donepezil in Alzheimer's disease - results from a multinational trial. Dement Geriatr Cogn Disord 1999;10:237-44.
4. Blau, TH. Quality of life, social indicators and criteria of change. Professional Psychology 1977;8:404-73.
5. Bodick NC, Offen WW, Levey AI, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 1997;54:465-73.
6. Cummings JL, Cyrus PA, Bieber F, et al. Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Metrifonate Study Group. Neurology 1998;50:1214-21.
7. Cummings JL, Kaufer D. Neuropsychiatric aspects of Alzheimer's disease: The cholinergic hypothesis revisited. Neurology 1996;47:876-83.
8. Doody RS. Treatment of Alzheimer's Disease. The Neurologist 1997;3: 279-89.
9. Doody RS, Massman P, Mahurin R, Law S. Positive and negative neuropsychiatric features in Alzheimer's disease. J Neuropsychiatry Clin Neurosci 1995;7:54-60.
10. Francis PT, Palmer AM, Snape M, Wilcock GK. The cholinergic hypothesis of Alzheimer's disease: a review of progress. J Neurol Neurosurg Psychiatry 1999;66:137-47.
11. Folstein MF, Folstein SE, McHugh PR. "Mini-Mental State": A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
12. Gorman DG, Read S, Cummings JL. Cholinergic therapy of behavioral disturbances in Alzheimer's disease. Neuropsychiatry Neuropsychol Behav Neurol 1993;6:229-34.
13. Knopman D, Schneider L, Davis K, et al. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality. Neurology 1996;47:166-77.
14. Mega SM, Cummings JL, Fiorello T, Gornbein J. The spectrum of behavioral changes in Alzheimer's disease. Neurology 1996;46:130-5.
15. Morris JC. The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology 1993;43:2412-4.
16. Morris JC, Cyrus PA, Orazem J, et al. Metrifonate benefits cognitive, behavioral, and global function in patients with AD. Neurology 1998;50:1222-30.
17. Nitsch RM, Slack BE, Wurtman RJ, Growdon JH. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 1992;258:304-7.
18. Paganini-Hill A, Henderson VW. Estrogen replacement therapy and risk of Alzheimer disease. Arch Intern Med 1996;156:2213-7.
19. Raskind MA, Sadowsky CH, Sigmund WR, et al. Effect of tacrine on language, praxis, and noncognitive behavioral problems in Alzheimer disease. Arch Neurol 1997;54:836-40.
20. Rogers SL, Cooper NM, Sukovaty R, et al. Pharmacokinetic and pharmacodynamic profile of donepezil HCl following multiple oral doses. Br J Clin Pharmacol 1998a;46(Suppl 1):7-12.
21. Rogers SL, Doody RS, Mohs RC, et al. Donepezil improves cognition and global function in Alzheimer's disease: a 15-week, double-blind, placebo-controlled study. Arch Intern Med 1998b;158:1021-31.
22. Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998c;50:136-45.
23. Rogers SL, Friedhoff LT. Donepezil is well tolerated at clinically effective doses for the treatment of Alzheimer's disease. Eur Neuropsychopharmacol 1997;7(S2):S251.
24. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatr 1984;141:1356-64.
25. Rother M, Erkinjuntti T, Roessner M, et al. Propentofylline in the treatment of Alzheimer's disease and vascular dementia: a review of phase III trials. Dement Geriatr Cogn Disord 1998;9(Suppl 1):36-43.
26. Samuels SC, Davis KL. A risk assessment of tacrine in the treatment of Alzheimer's disease. Drug Safety 1997;16:66-77.
27. Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both, as treatment for Alzheimer's disease. N Engl J Med 1997;336:1216-22.
28. Schneider L, Olin J, Doody RS, et al. Validity and reliability of the Alzheimer's Disease Cooperative Study Unit Clinical Global Impression of Change (ADCSU-CGIC). Alzheimer Dis Assoc Disord 1997;11:522-32.
29. Steele C, Rovner B, Chase GA, Folstein M. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psychiatry 1990;147:577-87.
30. Teunisse S, Derix MMA, van Crevel H. Assessing the severity of dementia: Patient and caregiver. Arch Neurol 1991;48:274-7.
31. Thal LJ, Ferguson JM, Mintzer J, et al. A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer's disease. Neurology 1999;52:1146-52.
32. US Package Insert. Aricept® (donepezil hydrochloride tablets), September 1998.